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ARTICLE
A Large-Scale Genetic Association Study Confirms IL12B
and Leads to the Identification of IL23R as Psoriasis-Risk Genes
Michele Cargill,*,† Steven J. Schrodi,* Monica Chang, Veronica E. Garcia, Rhonda Brandon,
Kristina P. Callis, Nori Matsunami, Kristin G. Ardlie,‡ Daniel Civello, Joseph J. Catanese,
Diane U. Leong, Jackie M. Panko, Linda B. McAllister,§ Christopher B. Hansen, Jason Papenfuss,
Stephen M. Prescott,k Thomas J. White, Mark F. Leppert, Gerald G. Krueger, and Ann B. Begovich
We performed a multitiered, case-control association study of psoriasis in three independent sample sets of white North
American individuals (1,446 cases and 1,432 controls) with 25,215 genecentric single-nucleotide polymorphisms (SNPs)
and found a highly significant association with an IL12B 3′-untranslated-region SNP (rs3212227), confirming the results
of a small Japanese study. This SNP was significant in all three sample sets (odds ratio [OR]common 0.64, combined P
). A Monte Carlo simulation to address multiple testing suggests that this association is not a type510[P ]p 7.85# 10comb
I error. The coding regions of IL12B were resequenced in 96 individuals with psoriasis, and 30 additional IL12B-region
SNPs were genotyped. Haplotypes were estimated, and genotype-conditioned analyses identified a second risk allele
(rs6887695) located ∼60 kb upstream of the IL12B coding region that exhibited association with psoriasis after adjustment
for rs3212227. Together, these two SNPs mark a common IL12B risk haplotype (ORcommon 1.40, ) and
59P p 8.11# 10comb
a less frequent protective haplotype (ORcommon 0.58, ), which were statistically significant in all three
512P p 5.65# 10comb
studies. Since IL12B encodes the common IL-12p40 subunit of IL-12 and IL-23, we individually genotyped 17 SNPs in
the genes encoding the other chains of these cytokines (IL12A and IL23A) and their receptors (IL12RB1, IL12RB2, and
IL23R). Haplotype analyses identified two IL23R missense SNPs that together mark a common psoriasis-associated hap-
lotype in all three studies (ORcommon 1.44, ). Individuals homozygous for both the IL12B and the IL23R
56P p 3.13# 10comb
predisposing haplotypes have an increased risk of disease (ORcommon 1.66, ). These data, and the
58P p 1.33# 10comb
previous observation that administration of an antibody specific for the IL-12p40 subunit to patients with psoriasis is
highly efficacious, suggest that these genes play a fundamental role in psoriasis pathogenesis.
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Psoriasis is a common, chronic, T-cell–mediated inflam-
matory disease of the skin, affecting ∼2%–3% of whites
of European descent. Although this disease is found in all
populations, its prevalence is lower in Asians and African
Americans and also declines at lower latitudes.1 The most
common form, psoriasis vulgaris, is characterized by vary-
ing numbers of red, raised, scaly skin patches that can be
present on any body surface but that most often appear
on the elbows, knees, and scalp. The onset of disease usu-
ally occurs early in life (ages 15–30 years) and affects males
and females equally. Up to 30% of individuals with pso-
riasis will develop an inflammatory arthritis, which can
affect the peripheral joints of the hands and feet, large
joints, or the central axial skeleton.2,3 Pathologically, pso-
riasis is characterized by vascular changes, hyperprolifer-
ation of keratinocytes, altered epidermal differentiation,
and inflammation.4 In particular, the reaction of cells in
the epidermis to type 1 effector molecules produced by T-
cells results in the characteristic pathology of the plaques.5
The genetics of psoriasis are complex, and this disease
is highly heritable, as evidenced by an increased rate of
concordance in MZ versus DZ twins (35%–72% vs. 12%–
23%, respectively) and a substantially increased incidence
in family members of affected individuals (e.g., 6% for
first-degree relatives); however, it is clear that environ-
mental effects are also responsible for disease susceptibil-
ity.5 Ten genomewide linkage scans have resulted in strong
evidence of a susceptibility locus (PSORS1 [MIM #177900])
in the major histocompatibility complex (MHC) on 6p21
but have not yielded consistent evidence for other regions
(for a review, see the work of Bowcock and Kreuger5).
Linkage and association in the MHC (6p21) are thought
to be due to human leukocyte antigen (HLA)–C. In par-
ticular, psoriasis-susceptibility effects are thought to be
caused by the *0602 allele,6,7 although other candidate
genes in the region may also contribute to disease pre-
disposition. Association studies have identified three gene
regions under linkage peaks with considerable evidence
of linkage disequilibrium (LD) with psoriasis—namely,
SLC9A3R1/NAT9 and RAPTOR (KIAA1303) in 17q25 and
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SLC12A8 in 3q21.8,9 Several other genes—including IL12B
(MIM 161561), VDR, MMP2, IL10, IL1RN, and IRF2 (Ge-
netic Association Database)—have been associated with
psoriasis in sample sets of varying sizes and of different
ethnicities; however, without more data from additional
independent studies, it is difficult to draw statistically
sound conclusions about whether or not they are true
disease genes.
Genomewide association studies have been promoted
as a powerful method for the mapping of complex traits,
and both direct (i.e., with use of protein-altering markers)
and indirect (i.e., with tag SNPs or spaced markers) strat-
egies have been proposed.10–12 We undertook a large, gene-
centric association study that focused primarily on puta-
tive functional SNPs, to identify psoriasis-susceptibility
markers in white North American case-control samples,
and attempted to replicate significant markers in a second
independent case-control sample set. During this process,
we observed significant association of a SNP (rs3212227)
in the 3′ UTR of IL12B with psoriasis in both case-control
sample sets, confirming the results observed in a single
Japanese study.13
To explore the role of IL12B in the genetics of psoriasis
and to identify potentially causative variants, we geno-
typed additional markers in and around IL12B and per-
formed further analyses, including haplotype analyses. Be-
cause IL12B encodes the IL-12p40 subunit of two distinct
heterodimeric cytokines—IL-12 and IL-2314—we analyzed
SNPs in IL12A, IL23A (encoding the IL-12p35 and IL-
23p19 subunits, respectively), and the genes encoding the
receptors of IL-12 and IL-23 (IL12RB1, IL12RB2, and IL23R
[MIM 607562]), to determine if polymorphisms within
these IL12B-related genes also play a role in psoriasis sus-
ceptibility. Finally, we replicated all interesting findings in
a third independent white North American sample set.
Subjects and Methods
Overall Strategy
We conducted three sequential case-control studies (i.e., discov-
ery, replication 1, and replication 2), to identify SNPs associated
with psoriasis. In the discovery study, DNA samples from indi-
viduals with (cases) and without (controls) psoriasis were geno-
typed for 25,215 SNPs, with the use of disease-phenotype–based
pooled DNA samples, to increase genotyping throughput and to
minimize DNA consumption. The allele frequency of each SNP
was determined as described elsewhere,15 and SNPs associated
with psoriasis at the .05 significance level were evaluated in an
independent sample set (replication 1 study), by use of a similar
pooling strategy. Non–MHC-linked SNPs that were associated
with psoriasis in the replication 1 study ( ) and had theP ! .05
same risk allele as in the discovery study were then individually
genotyped in both the discovery and the replication 1 sample
sets, to verify the results from the pooled DNA studies. SNPs that
were still significant ( ) were then interrogated in a thirdP ! .05
independent sample set (replication 2 study). Here, we report the
results of the most significant non-MHC SNP.
Subjects
The discovery samples consisted of 467 white individuals with
psoriasis and 500 white individuals who served as controls. All
subjects are of northern European ancestry and reside in Utah or
in adjacent regions of southern Idaho, the area served by the
University of Utah Hospital and Clinics. The individuals with
psoriasis were recruited from the University of Utah Department
of Dermatology clinics, as part of the Utah Psoriasis Initiative
(UPI), and had a diagnosis of psoriasis confirmed by a UPI in-
vestigator. A full clinical workup and a questionnaire were avail-
able for each individual with psoriasis, and samples from first- or
second-degree relatives were not included in the study. Samples
from 500 white individuals matched for sex and ethnicity were
selected from the CEPH Utah (CEU) population ( grand-np 112
parents) and from other University of Utah research studies
( ) to serve as controls. The other research studies includenp 388
those of colon cancer, restless legs, smoking addiction, epilepsy,
and retinal disorders, and all control subjects used in the study
described here were either control subjects in these other research
studies or were unrelated spouses from family studies. The 112
control subjects from the CEU population were ascertained with-
out regard to disease status. For the remaining 388 individuals,
information about autoimmune disease status was available from
53%, and any individual with psoriasis or another autoimmune
disease was excluded. Information about autoimmune disease
status was not available for the remaining 47%; however, we ex-
pect the frequency of psoriasis and other autoimmune diseases
in this control population to be similar to that of the general
Utah population. Note that, if any of these control subjects carry,
with increased frequency, alleles for autoimmune diseases that
are also found for psoriasis, the significance of the results reported
here would increase if those controls were removed.
The replication 1 sample set was collected by the Genomics
Collaborative Division of SeraCare Life Sciences (GCI). Samples
were included from 498 unrelated white North American indi-
viduals with a dermatologist-confirmed diagnosis of psoriasis and
a Psoriasis Area and Severity Index (PASI) score and from 498
unrelated white North American individuals without a history
of psoriasis or other autoimmune disorders and individually
matched to the cases by sex and age. The replication 2 sample
set, consisting of samples from 481 unrelated white North Amer-
ican individuals with a dermatologist-confirmed diagnosis of pso-
riasis and from 424 unrelated white North Americans without
psoriasis, was used to confirm results from the two previous sam-
ple sets; samples from 293 individuals with psoriasis and 292
individuals without psoriasis were provided by GCI and met the
criteria described above. BioCollections Worldwide provided an
additional 188 samples from individuals with psoriasis who met
the same criteria described above, as well as samples from 132
white North Americans without psoriasis.
All individuals included in this study were 18 years or older at
the time they were enrolled in the sample collections. In addition,
none of the subjects had undergone a bone-marrow transplant.
All protocols were approved by national and/or local institutional
review boards, and informed written consent was obtained from
all subjects. A detailed breakdown of the clinical characteristics
of the discovery and replication 1 sample sets is provided in table
1. Detailed clinical information for all individuals with psoriasis
in the replication 2 sample set was limited. The female:male sex
ratio was 0.89, and the average (SD) age of onset was 28  16
years.
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Table 1. Demographic and Clinical Information
Subphenotypea
Sample Set
Discovery Replication 1
Genetic background White (Utah) White (North America)
No. of cases 467 498
No. of controls 500 498
Female:male sex ratio 1.2 1.2
Average age at onset (years) 28  17 29  15
Percentage with family history of psoriasis 62.70% 46.60%
No. of cases with:
Psoriatic arthritis and psoriasis for at least 10 years (yes/no) 125/239 98/143
National Psoriasis Foundation score !7.5/7.5–12.5/112.5 124/132/129 …
PASI score !10/10–50/150 … 364/103/4
a Data for certain subphenotypes were not available for all patients.
Scan SNP Selection
Allele-specific, kinetic PCR assays were developed for a collection
of 25,215 genecentric SNPs curated from dbSNP, the Applera Ge-
nome Initiative,16,17 and the literature. SNPs were selected for in-
clusion if they appeared in more than one database and had a
minor-allele frequency (MAF) 1%. Of the SNPs, ∼70% are mis-
sense polymorphisms predicted to modify the amino acid se-
quences encoded by the genes. The majority of the remaining
30% of SNPs were splice-site acceptors or donors, putative tran-
scription-factor binding sites, etc. Of the SNPs, ∼75% have MAFs
5%.
Allele Frequency and Genotype Determination
SNP allele frequencies in pooled DNA samples were determined
by allele-specific, kinetic PCR, as described elsewhere.15,16 In brief,
3 ng of pooled DNA was amplified using allele-specific primers
and allele frequencies calculated from the two allele-specific PCR
amplification curves, each determined in duplicate. Individual
genotyping was performed using allele-specific kinetic PCR on
0.3 ng of DNA, and the data were hand curated before statistical
analysis, without knowledge of case-control status. Genotyping
calls were made on 199% of samples, for all SNPs genotyped.
Previous analyses suggest a genotyping accuracy of 199%.18,19 Ge-
notyping of the four most interesting SNPs described here (i.e.,
rs3212227, rs6887695, rs7530311, and rs11209026) in 320 of the
psoriasis study samples, with use of an unrelated technology—a
multiplexed oligoligation assay—showed 199.8% concordance.
HLA-C genotypes were determined for the discovery samples by
high-resolution sequence-based typing (performed by Atria Ge-
netics). HLA-C genotypes were not available for the other two
sample sets.
Pools were constructed using an orthogonal design in which
an individual DNA sample was arrayed into multiple pools on
the basis of clinically relevant phenotypes. For the unstratified
analyses (i.e., all cases vs. all controls), the allele-frequency mea-
surements in each stratum were combined and averaged on the
basis of the formula
1 2
frequencyp f p ,  i ij( )[ ]2n lj ij
where is the number of pools in which sample appears,l jj
if sample j belongs to pool i and is 0 otherwise, is thep p 1 fij i
allele-frequency estimate in pool i, and n is the number of distinct
samples across all pools. By using an orthogonal pooling strategy
based on clinically relevant phenotypes and by collapsing all the
strata into an analysis of all cases versus all controls, we were
essentially taking repeated measurements and were able to reduce
measurement error for the comparison of all cases versus all
controls.
IL12B Sequencing
To identify novel variants of IL12B, we selected DNA for rese-
quencing from 96 randomly chosen individuals with psoriasis in
the replication 1 sample set. Sequence data from all eight an-
notated exons and from the 5,000 bp upstream of the 5′-most
exon of IL12B, which spans ∼17 kb, were extracted from the R27
draft of the Celera human genome sequence (Entrez Nucleotide
[accession number NW_922784]). Primers were designed using
the Primer3 program20 and included the M13 forward (5′ primer)
or reverse (3′ primer) universal sequencing primer-binding se-
quence at their 5′ ends. PCR amplification and sequencing were
performed as described elsewhere.19
SNP Selection for Follow-Up Genotyping
Tag SNPs for follow-up genotyping were selected by downloading
the CEU HapMap genotypes between positions 158,464,177 and
158,828,966 on chromosome 5 from the HapMap Web site (re-
lease 12, October 2004) and by running the computer program
Redigo.21 The approach used by this program maximizes the sta-
tistical power to detect truly associated SNPs, while minimizing
the number of SNPs that are genotyped, and does not use mea-
sures of LD to select the SNPs. For the power calculations, we set
the following parameters: 500 cases, 500 controls, 0.95 power
threshold, disease prevalence 0.01, and a conservative disease
model (additive mode of inheritance with genotypic relative risk
[GRR] 1.5). As described by Hu and colleagues,21 use of a conser-
vative disease model produces a tag SNP set that can exhibit mod-
erate-to-substantial LD between pairs of selected SNPs and is also
robust to changes in disease models.
LD Analysis and Haplotype Estimation
The LD measure was calculated from unphased data with use2r
of the LDMAX program in the GOLD package.22 Spotfire software
was used to generate graphical representations of the LD matrix.2r
A pseudo-Gibbs sampling algorithm from the program SNPAna-
lyzer version 1.023 was used to estimate haplotype and diplotype
frequencies from unphased data. Cases and controls were treated
separately in this process. The Haplo.Stats package, which cal-
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culates global P values (P values that test the null hypothesis of
independence between disease status and all the haplotypes) as
well as P values for each individual predicted haplotype, was used
to test for association between haplotypes and disease status.24
The Haplo.Stats package is particularly useful for unphased data,
since it adjusts the variance on the test statistic for haplotype
estimation error.
Association Statistics
A test of independence between allelic counts and disease status
was performed using Fisher’s exact test.25 For larger contingency
tables, the Williams-corrected G test was applied, to evaluate the
null hypothesis of independence between genotype counts and
psoriasis status,26 except when the data were sparse. In that sit-
uation, a Monte Carlo simulation approach was used to obtain
appropriate P values. To explore the extent of deviation from
Hardy-Weinberg equilibrium (HWE), Weir’s exact test for HWE
was calculated.27 Since many disease models will predict a dif-
ference in pairwise LD between samples from affected individuals
and samples from unaffected individuals, we used the LD contrast
test, described by Nielsen and colleagues,28 to test for differences
in LD patterns between cases and controls. We employed Fisher’s
combined P value to perform a joint analysis across independent
studies. A Mantel-Haenszel common odds ratio (OR) was calcu-
lated across independent studies.26 GRR estimates (denoted as g)
were calculated using a Bayesian approach modeling (i) the prev-
alence of disease as a beta distribution having an expected disease
prevalence of 2.3% and (ii) the genotype counts as multinomially
distributed with parameters estimated from the empirical data.
The Breslow-Day statistic29 was used to determine whether SNPs
exhibited significant heterogeneity of ORs across subphenotypes.
Estimates of the population-attributable fraction were calculated
as described by Walter30 and Schlesselman.31
Since false-positive results can be problematic in any large-scale
experiment in which modest nominal significance levels are used,
we performed a Monte Carlo simulation to obtain the distribution
of combined P values across the two studies. Two null hypotheses
were considered, and the results were presented under each hy-
pothesis. Under the first model, which assumed independence
between the cases and controls and a uniform distribution of P
values, we generated 26,000 stochastically independent P values,
retaining the top 1,500 most significant. A second set of 1,500 P
values were then generated under a uniform distribution, to sim-
ulate P values for the replication data set, and the two P values
for each replicate were combined using Fisher’s combined P value.
The entire in silico experiment was repeated 1,000 times. The
single most significant P value from each in silico experiment was
then used to generate a distribution of the 1,000 most significant
experimentwide P values. This is analogous to results obtained
under the Dunn-Sidak–corrected significance level (similar to a
Bonferroni correction).26 For the second model, we took a similar
approach, except that we used the results from the pooled dis-
covery samples to model the distribution of null P values. This
approach is typically more conservative and is described in detail
by Schrodi.32 The resulting gamma-null model was defined by
scale and shape parameters of 1.2032 and 0.8517, respectively.
Similar to other empirically based methods used in large-scale
studies to obtain null or alternative models,33 this gamma-model
method concurrently adjusts for diffuse effects of population
stratification in a way similar to genomic control approaches.34
In an approach similar to the haplotype method,35,36 we per-
formed tests of association for a specific SNP conditional on ge-
notypes at other SNPs. That is, cases and controls were both par-
titioned on the basis of genotypes at one SNP, and the counts at
an interrogated SNP were used in a test statistic. The statistical
significance of the resulting test statistic was assessed using a
permutation procedure. This type of test is useful in dissecting
the relative contribution of each SNP to disease association for a
set of SNPs in LD.
To explore the likelihood of our data under various disease
models, we calculated Bayes factor curves,37,38 using data from all
three studies. The results were compared against the likelihood
of the data under a null hypothesis that accounts for diffuse pop-
ulation stratification. Mathematically, the Bayes factor can be
written as , where is the allelicB (R)p P(DataFH F)/P(DataFH F) RD 0
relative risk, is the disease model, which is a function of R,HD
and H0 is the null hypothesis.
32
Results
Discovery Scan and Replication Data
A genecentric set of 25,215 SNPs was genotyped in pooled
discovery samples consisting of 466 white North Ameri-
can individuals with psoriasis and 500 white North Amer-
ican control individuals from Utah (see “Subjects and
Methods” section and table 1). DNA for 1 of the 467 pa-
tients was not available at the time the pools were con-
structed. This set of SNPs was highly enriched for mis-
sense, nonsense, and regulatory polymorphisms.16 The
discovery scan on DNA pools yielded 1,654 markers with
nominal P values !.05, 130 of which mapped within or
near the MHC. These markers were then genotyped in
pooled replication 1 samples consisting of 498 white, un-
related North American individuals with psoriasis and 498
white, unrelated North American controls matched for age
and sex. Given that the MHC harbors the major suscep-
tibility locus for psoriasis (the frequency of the psoriasis-
risk HLA allele, C*0602, was 22.4% in our discovery cases
vs. 8.5% in the controls; OR 3.10 [95% CI 2.37–4.08],
) and given the strong LD known to exist17Pp 2.37# 10
across this region,39 it is not surprising that 71 of the MHC-
linked SNPs had P values !.05 in the replication 1 sample
set, confirming the validity of this tiered approach to iden-
tify disease alleles. The most significant non–MHC-linked
marker across both studies was rs3212227, an ArC SNP
in the 3′ UTR of IL12B, located on 5q (pooled discovery
samples ; pooled replication 1 samples5Pp 5.24# 10
). This gene encodes the common IL-8Pp 1.88# 10
12p40 subunit of two cytokines, IL-12 and IL-23,14 and
insertions and deletions in this gene have been associated
with a rare, recessive form of Mendelian susceptibility to
mycobacterial disease (MIM 209950).40,41
Individual genotyping of rs3212227 in the discovery
and replication 1 samples and analyses of HWE showed
that we could not reject HWE for this SNP in the cases
and controls in either sample set ( in discoveryPp .847
cases and in discovery controls; in rep-Pp .588 Pp .297
lication 1 cases and in replication 1 controls) andPp .913
confirmed association of the A (major) allele with risk of
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Table 2. Case-Control Allelic Association Analysis of
rs3212227
Sample Set
and Allele
No. (Frequency) in
Risk Allele OR
(95% CI)a PbCases Controls
Discoveryc:
C 133 (.143) 192 (.209) … …
A 799 (.857) 726 (.791) 1.59 (1.25–2.03) 1.89#104
Replication 1:
C 135 (.137) 219 (.223) … …
A 849 (.863) 763 (.777) 1.81 (1.42–2.28) 7.59#107
Combined … … 1.70 (1.43–2.01) 3.39#109
a ORs for the discovery and replication 1 sample sets were deter-
mined for the common risk allele with the use of standard methods.
For the combined analysis, we used the method of Mantel-Haenszel.
b Allelic P values for the discovery and replication 1 sample sets
were calculated using Fisher’s exact test. Allelic combined P values
were determined using Fisher’s combined test.
c Individual genotyping was performed for 467 cases and 460 con-
trols from the discovery sample set.
Table 3. Case-Control Genotypic Association Analysis
of rs3212227
Sample Set
and Genotype(s)
No. (Frequency) in
OR (95% CI)a gbCases Controls
Discoveryc,d:
CC 10 (.021) 22 (.047) … …
CA 113 (.242) 148 (.322) … …
AA 343 (.736) 289 (.630) … …
CA vs. CC … … 1.68 (.76–3.69) 1.67
AA vs. CC … … 2.61 (1.22–5.60) 2.57
AA  CA vs. CC … … 2.29 (1.07–4.90) 2.27
Replication 1e:
CC 12 (.024) 24 (.049) … …
CA 111 (.226) 171 (.348) … …
AA 369 (.750) 296 (.603) … …
CA vs. CC … … 1.30 (.62–2.70) 1.29
AA vs. CC … … 2.49 (1.23–5.07) 2.45
AA  CA vs. CC … … 2.06 (1.02–4.16) 2.03
Combinedf:
CA vs. CC … … 1.47 (.86–2.50) …
AA vs. CC … … 2.55 (1.52–4.28) …
AA  CA vs. CC … … 2.16 (1.29–3.63) …
a ORs for the discovery and replication 1 sample sets were de-
termined for the common risk allele with the use of standard meth-
ods. For the combined analysis, we used the method of Mantel-
Haenszel.
b GRR estimates for the indicated genotypes, calculated using
a Bayesian approach as described in the “Subject and Methods”
section.
c Individual genotyping was performed for 467 cases and 460
controls from the discovery sample set.
d , calculated using a Williams-corrected G test.Pp .001
e , calculated using a Williams-corrected G test.6Pp 4.17# 10
f , determined using Fisher’s combined test.8Pp 8.68# 10
psoriasis (discovery sample set OR 1.59, ;4Pp 1.89# 10
replication 1 sample set OR 1.81, ), with7Pp 7.59# 10
a Fisher’s combined allelic P value of and an93.39# 10
ORcommon of 1.70 (table 2) (see below for a detailed discus-
sion of experimentwide significance). The common A al-
lele is increased in cases compared with controls (∼86%
vs. ∼78%–79%, respectively). The association at rs3212227
appears to be independent of HLA-C, since stratification
of the discovery data by presence or absence of the HLA-
C*0602 risk allele did not result in significantly different
ORs (1.47 and 1.61, respectively; Breslow-Day ).Pp .88
Genotypic analysis of rs3212227 is presented in table 3.
In a combined analysis of both sample sets, we found that
the heterozygous genotype confers a modest, although
not statistically significant, risk of psoriasis when com-
pared with the minor homozygote genotype (ORcommon
1.47 [95% CI 0.86–2.50]), whereas individuals homozy-
gous for the A allele appear to be at greater risk for psoriasis
relative to the minor homozygote (ORcommon 2.55 [95% CI
1.52–4.28]). We also calculated Bayesian estimates of GRR
(g) for both the AA and CA genotypes (relative to the CC
genotype) in each sample set, assuming that disease prev-
alence was beta distributed, with a mean of 2.3% (table
3). The resulting GRR estimates, which are quite similar
to the ORs, are also consistent with a general model of
inheritance, in which individuals carrying one copy of the
A allele at rs3212227 have an increased risk of psoriasis
relative to noncarriers, and individuals carrying two copies
have an even greater risk.
Since false-positive results can be problematic in any
large-scale experiment, we performed a Monte Carlo sim-
ulation, to obtain an experimentwide significance level.
Two null hypotheses were considered, and results were
presented under each. Under the first null model, which
generates results similar to a Dunn-Sidak– or Bonferroni-
corrected significance level,26 we assumed independence
between the cases and controls, generating a uniform dis-
tribution of P values (see the “Association Statistics” sub-
section). The resulting combined P values, which repre-
sent 1,000 independent in silico experiments, ranged from
to (uniform model) (fig. 1). None4 82.73# 10 2.58# 10
of these are as significant as the calculated Fisher’s com-
bined P value of for the IL12B 3′ UTR SNP,93.39# 10
rs3212227. The second model (gamma model) (fig. 1),
which uses the results from the pooled discovery samples
to model the distribution of null P values and is more
conservative,32 yielded 1,000 null combined P values rang-
ing from to . Only one exceeded4 91.53# 10 2.30# 10
the significance of the Fisher’s combined P value of
for the IL12B 3′ UTR SNP. Taken together,93.39# 10
these data suggest that association of the IL12B 3′ UTR
SNP with psoriasis is unlikely to be a type I error.
IL12B Sequencing in Patients with Psoriasis
To identify novel IL12B SNPs in patients with psoriasis,
we sequenced 1,136 bases of 5′ sequence, all exons and
intron/exon boundaries, and 1,424 bases of 3′ sequence
of IL12B in 96 individuals with psoriasis from the repli-
cation 1 sample set. On average, we successfully sequenced
89 individuals (coverage ranged from 70 to 96 individuals)
and identified six SNPs, only one of which was not found
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Figure 1. Results from the Monte Carlo simulation, showing the
distribution of the 1,000 most significant combined P values under
two null models. The arrow indicates the P value for rs3212227
( ).93.39# 10
in public databases. The minor allele of this novel 3′ UTR
SNP (C158674941T; ss52085990) was observed on only
one chromosome in the 96 individuals sequenced and was
not genotyped further in this study.
Single-Marker Analysis of the IL12B Region
To further explore the association signal in the IL12B re-
gion, we first chose to determine whether other alleles
within the IL12B region were associated with psoriasis by
genotyping a combination of tag SNPs, which had the
highest average power to detect disease-associated variants
under a conservative disease model, and functional SNPs
in our discovery and replication 1 sample sets. Of the 32
tag SNPs we selected using the program Redigo,21 from a
total of 44 CEU phase I HapMap SNPs42 in a region of
364.8 kb surrounding IL12B on chromosome 5, 27 pro-
duced high-quality individual genotyping data in both
the discovery and replication 1 sample sets, with minimal
loss in average power (0.89 for 27 tag SNPs vs. 0.90 for 32
tag SNPs). We also individually genotyped a putative pro-
moter polymorphism upstream of IL12B—rs17860508,43,
44 which has been shown to affect IL-12 and IL-12Bp40
protein levels in stimulated cells, albeit inconsistently44–
47—as well as two validated (SeattleSNPs resource) IL12B
missense SNPs (rs3213119 and rs3213096) (fig. 2 and table
4), for a total of 30 additional SNPs in the IL12B region.
An exact test of HWE of the genotypic data for these 30
variants, with the analysis performed separately for cases
and controls in each sample set (data not shown), iden-
tified only two instances where a marker was not in HWE
at the significance level (rs7721001 in the discoveryP ! .05
controls, ; rs270654 in the replication cases,Pp .005
).Pp .020
All 30 variants were analyzed for single-marker associ-
ation with psoriasis susceptibility. In addition to the orig-
inal hit, three other SNPs—rs3212220, rs7709212, and
rs6887695, all of which lie upstream of the IL12B ATG
start codon—had P values !.05 in an allelic test, with con-
sistent ORs (i.e., the psoriasis-risk allele was the same) in
both sample sets (table 4). The results for the putative
promoter polymorphism, rs17860508, did not reach sta-
tistical significance in the discovery sample set (Pp
) and were only marginally significant in the repli-.056
cation 1 sample set ( ). The two missense SNPs,Pp .031
which were relatively infrequent in our sample sets
(rs3213119, F298V: allele frequency ∼3%–4%; rs3213096,
I33V: allele frequency !1%), were not significantly asso-
ciated with disease.
LD and Haplotype Analysis of the IL12B-Region SNPs
We examined the LD patterns in this region by calculating
the pairwise values between all 31 markers separately2r
for the cases and the controls in each study (fig. 3). The
original hit, rs3212227, is in high LD with one of the tag
SNPs, rs3212220 ( in the cases and the controls of2r 1 0.97
both sample sets), and is in modest LD with rs1897565
( –0.33), rs17860508 ( –0.23), rs77092122 2r p 0.25 r p 0.12
( –0.40), and rs6887695 ( –0.31) but ex-2 2r p 0.28 r p 0.15
hibits little to no LD with the other 25 SNPs. Four other
marker pairs show moderate LD ( ) in the20.50 ! r ! 0.80
cases and the controls of both sample sets; however, the
majority of the markers exhibited minimal LD between
one another.
To focus on regions of interest, we generated three-
marker sliding-window haplotypes for the 28 markers
with a MAF 15% for the cases and the controls from both
sample sets. Global P values were determined using the
Haplo.Stats program,24 to assess the overall haplotype-fre-
quency differences between the cases and the controls for
each 3-SNP window (fig. 4). Two peaks with highly sig-
nificant global P values ( ) were observed in bothP ! .0001
sample sets. The first peak (w14-17) centers on the original
marker, rs3212227, and on rs3212220, which, as noted
above, are in strong LD with one another. The second peak
(w22-24) centers on rs6887695. These three markers also
showed the most-significant single-marker association
(table 4).
On the basis of these results, we focused subsequent
analyses on the 13 SNPs with a MAF 15% and encom-
passed by these two peaks (rs11744690 to rs4921226 in
table 4). Haplotypes for all 13 SNPs across this 144-kb
region were predicted, and association between these
haplotypes and disease status was determined using
Haplo.Stats. This was followed by the stepwise removal of
each SNP and reanalysis of the haplotypes and their as-
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Figure 2. The physical map of the 360 kb around IL12B on human chromosome 5. Four known genes map to the area: EBF, FLJ31951,
UBLCP1, and IL12B. AK097548 is a gene model with one mRNA as supporting evidence. Thirty-one markers spanning this region were
genotyped in two independent case-control psoriasis sample sets. These markers included 27 tag SNPs, 1 putative promoter SNP
(rs17860508), 2 missense SNPs (rs3213119 and rs3213096), and the original hit, rs3212227. On the basis of a visual examination of
the CEU HapMap genotypes, 26 of the markers genotyped in the study map to a loosely defined block of LD. Blocks on either side of
this central region were queried using five additional markers.
sociation with disease, to define the minimum number of
SNPs that explained the observed association (data not
shown). This systematic approach indicated that 2 of these
13 SNPs—our original hit (rs3212227) and rs6887695,
which exhibit some LD ( –0.31)—could explain2r p 0.15
the majority, if not all, of the association with psoriasis
observed in both sample sets (table 5). The 2-SNP hap-
lotype containing the major allele of both SNPs (A at
rs3212227 and G at rs6887695) appears to be associated
with risk in both sample sets (discovery sample set OR
1.42, ; replication 1 sample set OR 1.48,4Pp 3.27# 10
), whereas a second haplotype containing5Pp 1.35# 10
the minor allele at both SNPs (C-C) confers protection
(discovery sample set OR 0.63, ; replication4Pp 5.8# 10
1 sample set OR 0.46, ). The frequencies9Pp 2.56# 10
of the other two haplotypes, which contain a risk allele
at one SNP and a protective allele at the second SNP, did
not exhibit substantial differences between cases and
controls.
Because these two markers (rs3212227 and rs6887695)
exhibited some LD, we performed genotype-conditioned
analyses similar to that described by Thomson and col-
leagues,35,36 to see if either SNP was associated with disease
independent of the other SNP. To do this, we calculated
a summary statistic for each sample set, using the geno-
types at one marker conditioned on the other marker,
and evaluated the significance of these observed results
through a permutation test. The results of 20,000 per-
mutations for each sample set demonstrated that associ-
ation of rs3212227 with psoriasis given rs6887695 (and
rs6887695 given rs3212227) was significant at the .001
level in both sample sets, indicating that each SNP con-
tributes independently to psoriasis risk.
Replication of IL12B Results in a Third Sample Set and in
Combined Analyses
We then genotyped rs3212227 and rs6887695 in a third
independent sample set consisting of 481 white North
American individuals with psoriasis and 424 white North
American controls. Allele frequencies were comparable
across all three sample sets, and single-marker analysis
confirmed that both rs3212227 and rs6887695 were as-
sociated with psoriasis in this independent sample set
( and , respectively) (table 4). The com-Pp .014 Pp .007
bined analysis for each individual SNP across all three
sample sets was highly significant (combined P [P ]pcomb
and , respectively). Hap-10 87.85# 10 P p 4.08# 10comb
lotypes were also estimated in the third sample set, con-
firming the common IL12B risk haplotype (OR 1.31,
) as well as the less frequent protective3Pp 6.00# 10
haplotype (OR 0.70, ) (table 5). The com-3Pp 7.00# 10
bined analyses across all three sample sets were highly
significant; the frequency of the common risk A-G hap-
lotype is ∼71%–72% in cases versus ∼64% in controls
(ORcommon 1.40, ), and the frequency of
9P p 8.11# 10comb
the protective C-C haplotype is ∼10%–12% in cases versus
∼17%–19% in controls (ORcommon 0.58, P p 5.65#comb
) (table 5). Importantly, the other two haplotypes car-1210
rying a risk allele at one SNP and a protective allele at the
other SNP were not associated with psoriasis. Together,
these data provide convincing statistical evidence that the
IL12B region on 5q31.1-33.1 harbors a psoriasis-suscep-
tibility locus.
Analysis of IL12B-Related Genes
IL12B encodes the common IL-12p40 subunit of two het-
erodimeric cytokines, IL-12 and IL-23, each with a distinct
subunit encoded by the genes IL12A (IL-12p35) and IL23A
(IL-23p19). The IL-12 and IL-23 receptors also share a com-
mon subunit encoded by IL12RB1, in addition to their
unique components—IL23R for the IL-23 receptor and
IL12RB2 for the IL-12 receptor. To determine whether var-
iants of these candidate genes might be associated with
psoriasis, we individually genotyped 17 SNPs (7 in IL12A,
2 in IL23A, 4 in IL12RB1, 1 in IL12RB2, and 3 in IL23R)
from our collection of assays in the discovery sample set.
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Figure 3. Pairwise LD between the 31 IL12B-region SNPs, as measured by r2 in the cases and controls of both the discovery and
replication 1 sample sets. The indexes of the SNPs (table 4) were arranged vertically from SNP 2 to SNP 31 and horizontally from SNP
1 to SNP 30.
Two SNPs, rs7530511 in IL23R (OR 0.67, ) andPp .006
rs2914119 in IL12A (OR 0.78, ), were nominallyPp .045
significant in the single-marker analyses ( ) (table 6).P ! .05
We also estimated haplotypes for all SNPs in each gene
(data not shown) and tested for association with disease
with the use of Haplo.Stats. Since IL23R and IL12RB2 lie
directly adjacent to each another on chromosome 1, all
four SNPs in these two genes were used together in the
haplotype analysis of this region. If the global P value for
all the SNPs in a particular gene was significant, we then
evaluated the contribution of each SNP to this signal, us-
ing a systematic stepwise approach in which each SNP was
removed and Haplo.Stats was rerun. Using this approach,
we found that a second IL23R SNP, rs11209026, in com-
bination with rs7530511, was associated with psoriasis risk
(global ) (table 7). The most common haplotypePp .004
marked by these two SNPs, C at rs7530511 and G at
rs11209026, was increased in patients compared with con-
trols (85.2% vs. 79.3%, OR 1.5, ) (table 7)4Pp 9.48# 10
and was more significant than each SNP individually
(table 6).
The two IL23R SNPs and the IL12A SNP were then in-
dividually genotyped in the replication 1 sample set (ta-
ble 6). The IL12A SNP did not replicate ( ), and aPp .955
meta-analysis of both discovery and replication 1 sam-
ples yielded a Fisher’s combined P value of .178 (data not
shown). However, the common IL23R haplotype, C at
rs7530511 and G at rs11209026, was associated with pso-
riasis risk in the replication 1 sample set (OR 1.37, Pp
), as well as in the replication 2 sample set (OR 1.45,.006
) (table 7), and the combined analysis across allPp .003
three sample sets was highly significant (ORcommon 1.44,
), providing strong statistical evidence6P p 3.13# 10comb
for a psoriasis-susceptibility gene on 1p31. It is interesting
to note that these two IL23R SNPs are both missense SNPs
(rs7530511, L310P; rs11209026, Q381R) with an r2 value
between them of !0.012 in the cases and controls of all
three sample sets (data not shown). The common risk hap-
lotype carries a proline at amino acid 310 and an arginine
at amino acid 381. Both of these amino acids are con-
served in the chimpanzee, mouse, rat, cow, dog, and
chicken.
Additional Statistical Support of IL12B and IL23R
Haplotypes
Complementing traditional homogeneity tests, significant
differences in LD patterns between cases and controls can
also indicate disease association. We applied the LD con-
trast test described by Nielsen and colleagues28 to pairs of
SNPs in IL12B and IL23R. The results show departures be-
tween case and control pairwise values of D at rs3212227-
rs6887695 for IL12B, as expected under a disease model:
, ,8P p .0129 P p 5.16# 10 P pcs-dis,ct-dis cs-rep1,ct-rep1 cs-rep2,ct-rep2
(where “cs” denotes cases,“ct” denotes controls,.0497
“dis” denotes the discovery sample, and “rep1” and “rep2”
denote replication sample sets 1 and 2, respectively), and
. With regard to rs7530511-rs112090268P p 1.05# 10comb
at IL23R, this test yielded similar significant P values:
, , ,P p .0085 P p .0019 P p .0019cs-dis,ct-dis cs-rep1,ct-rep1 cs-rep2,ct-rep2
and . Since population stratification6P p 5.30# 10comb
and other sampling irregularities can generate departures
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Figure 4. 3-SNP sliding-window analyses of the IL12B-region SNPs
of pairwise LD measures from their null distribution, we
performed the LD contrast test on all combinations of
control-control (i.e., discovery controls vs. replication 1
controls, discovery controls vs. replication 2 controls,
etc.), case-case, and case-control samples, to better un-
derstand the significance of our results. In all instances
for both genes, case-control comparisons were statistically
significant ( ), whereas the case-case and control-P ! .05
control comparisons were not (results not shown).
Bayes factor curves were calculated for the risk
rs3212227-rs6887695 IL12B haplotype and the risk
rs7530511-rs11209026 IL23R haplotype. Bayes factors
were adjusted for population stratification and were com-
bined across the three independent studies.33 The results
show a maximum log10B(R) of 6.85 for the IL12B haplo-
type data, occurring at . Given equal prior prob-Rp 1.41
abilities for disease and null models, the probability of
the disease hypothesis, given the data, is ∼7-million-fold
larger (at a disease model of ) than the probabilityRp 1.41
of the null hypothesis conditioned on the data. Further,
the log10 , as R spans 1.15 to 1.73, testifying to theB(R) 1 4
strength, robustness, and specificity of the result. Similar
results were observed for the IL23R haplotype data, with
a maximum log10B(R) of 5.78 at . Log10B(R) re-Rp 1.47
mains 14 for the relatively narrow range of 1.20 ! R !
.1.80
Diplotype Analyses
To better understand how the IL12B and IL23R genes in-
fluence an individual’s risk of psoriasis, we assessed the
impact of diplotypes at each locus independently and
then jointly on psoriasis risk. Of the 10 possible 2-SNP
IL12B diplotypes, 9 were observed in our samples (table
8). The combined results from all three sample sets suggest
that there is a hierarchy of risk depending on an individ-
ual’s IL12B diplotype. Psoriasis susceptibility appears to be
conferred by two copies of the common risk haplotype
(A-G/A-G ORcommon 1.52, ), which is7P p 6.14# 10comb
found in ∼48%–51% of cases versus 38%–40% of controls.
One copy of the risk haplotype (A-G) in combination
with a copy of a “neutral” haplotype (A-C or C-G) does
not appear to substantially affect psoriasis risk; however,
individuals who carry copies of both the risk and the
protective haplotypes (A-G/C-C) appear to be protected
(ORcommon 0.67, ). Individuals homo-4P p 1.39# 10comb
zygous for the protective haplotype (C-C/C-C) are rela-
tively uncommon (∼1% of cases vs. ∼2–3% of controls);
however, our data suggest that their risk of psoriasis may
be even lower (ORcommon 0.38, ), although,P p .018comb
given the stochastic variability around this estimate, ad-
ditional samples are required to fully address this issue.
The population-attributable fraction30,31 summarized across
all three sample sets for the homozygous susceptible A-G/
A-G IL12B diplotype, relative to all other diplotypes col-
lapsed together, was calculated to be 17.1% (95% CI
11.4%–22.5%).
At the IL23R locus, 7 of the 10 possible 2-SNP diplotypes
were observed (table 9). The data from all three sample
sets suggest that individuals homozygous for the suscep-
tible C-G haplotype are at increased risk of psoriasis
(ORcommon 1.48, ), whereas all other di-5P p 2.24# 10comb
plotypes appear to be neutral or protective. The estimated
population-attributable fraction summarized across all
three sample sets for the IL23R homozygous risk diplotype
(C-G/C-G), relative to all other diplotypes collapsed to-
gether, is 23.5% (95% CI 14.9%–31.5%).
To assess the joint impact of the IL12B and IL23R sus-
ceptible haplotypes, we determined the distribution of di-
plotypes at both genes, comparing cases and controls in
all three sample sets (table 10). Given the large number
of possible diplotypes across these two loci relative to the
number of cases and controls, we chose to concentrate
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our analysis on the risk haplotypes at each locus (A-G for
IL12B and C-G for IL23R) and to group the three nonrisk
haplotypes at each locus into a single haplotype (indicated
as “X” for both loci in table 10). The combined analysis
shows that individuals homozygous for both the IL12B
and IL23R predisposing haplotypes, ∼35%–37% of cases
versus ∼24%–27% of controls, appear to be at increased
risk of psoriasis (ORcommon 1.66, ). A
8P p 1.33# 10comb
much larger sample size is needed to thoroughly evaluate
the effect of all possible two-locus diplotypes; however, a
preliminary meta-analysis of the available data (using a
Bayesian approach, assuming no epistasis between loci
and an expected prevalence of psoriasis equal to 2% in
the general population) suggests at least a threefold dif-
ference in risk between individuals who carry one copy
of the protective C-C IL12B haplotype and one copy of
the protective C-A IL23R haplotype, representing 4.4% of
the general population (C-C/X–C-A/X, expected psoriasis
risk 0.84%) relative to individuals who are homozygous
for risk haplotypes at both loci, representing 25.5% of the
general population (A-G/A-G–C-G/C-G, expected psoriasis
risk 2.83%).
Discussion
We report the identification of two psoriasis-susceptibility
genes, IL12B and IL23R, in whites of European descent.
These genes were identified using a collection of 125,000
primarily functional SNPs evaluated in three independent
case-control sample sets (1,446 patients and 1,432 con-
trols) in a multistaged strategy that combined pooled and
individual genotyping, along with single-marker and mul-
timarker analyses. This approach, which was designed to
increase power while simultaneously making effective use
of genotyping resources and DNA, has been successfully
used to identify genetic variants associated with multiple
common, complex diseases, including rheumatoid arthri-
tis,48 myocardial infarction,16,49 liver fibrosis,50 Alzheimer
disease,51 and now psoriasis. Some of the genes identified
in these studies do not colocalize with known disease-
specific linkage peaks. Interestingly, IL23R (1p31.3) maps
within the broad PSORS7 1p linkage peak defined by Veal
and colleagues,52 whereas IL12B (5q31.1-q33.1) does not
map to any of the seven other major PSORS linkage peaks
reviewed by Bowcock and Kreuger.5 These data suggest
that our multitiered, genecentric case-control approach is
a highly effective strategy for identifying markers associ-
ated with common, complex diseases that complements
traditional linkage studies.
Our IL12B findings confirm and extend the observation
of Tsunemi et al.,13 who reported association of rs3212227
with risk of psoriasis in a Japanese study of 143 patients
and 100 controls ( in cases vs. 0.505 in con-f(A)p 0.601
trols, OR 1.47, ). Although the frequency of thePp .035
risk allele is quite different in Japanese (∼50.5%) compared
with white North American (∼78.5%) controls, this allele
exhibits a similar modest risk of psoriasis in both popu-
lations (OR 1.47 in Japanese vs. ORcommon 1.56 in white
North Americans). The decreased allele frequency of the
IL12B susceptibility allele in Japanese individuals relative
to white North American individuals parallels the differ-
ence in psoriasis prevalence in these two populations (1%
in Japanese vs. 2%–3% in white North Americans).53 No
other IL12B-associated SNPs were interrogated in the Jap-
anese study.
Although IL12B encodes the common IL12-p40 subunit
of both IL-12 and IL-23, IL-23 was discovered a decade
after IL-12. Consequently, early studies of IL-12 function,
which used either anti–IL-12p40 antibodies or IL-12p40–
deficient mice, attributed functions to IL-12 that are only
now being correctly ascribed to IL-23. Although this work
is still ongoing, it is clear that each cytokine has a unique
role in the immune response. Both are produced by ac-
tivated dendritic cells and macrophages; however, regu-
lation of their expression differs both spatially and tem-
porally. In addition, they drive the development of distinct
subsets of T-cells. IL-12 induces the classic interferon-g–
producing T-helper (Th) 1 cells, whereas IL-23 drives the
expansion and maintenance of the newly defined ThIL-
17 T cells (for a review, see the work of Hunter54 and Bow-
man et al.55).
Given that IL-12 drives the development of Th1 cells,
which play an important role in a subset of T-cell–medi-
ated autoimmune diseases, IL-12 and, more importantly,
rs3212227 have been studied in a number of immune-
mediated diseases. In addition to psoriasis, the A allele at
this SNP has been associated with type 1 diabetes,56 and
the C allele has been associated with diseases that can be
classified as type 2 diseases (those dominated by a humor-
al response), such as asthma,57 atopic dermatitis,13 and
chronic hepatitis C virus infection.58 However, with the
exception of psoriasis, most of these reported disease as-
sociations have not been replicated in independent stud-
ies. Other diseases, such as rheumatoid arthritis59,60 (A.
B. Begovich, S. J. Schrodi, and M. Chang, unpublished
data), Crohn disease,61,62 and systemic lupus erythema-
tosus,63 have not shown association with either allele at
rs3212227.
Although the effect of the 3′ UTR rs3212227 SNP on IL-
12 and IL-12p40 expression levels has been studied by
multiple groups, the results are inconsistent. When com-
pared with the C allele of this 3′ UTR SNP, the A allele has
been reported to be associated with (i) increased IL-12p40
secretion,64 (ii) no change in IL-12p40 secretion but de-
creased IL-12 secretion,61 (iii) increased IL12B mRNA,56 and
(iv) decreased IL-12 secretion.47 However, different cell
types and methods of cell stimulation and IL-12 quanti-
tation were used for these studies. To resolve this issue,
additional studies are required, and they should involve
specific cell types that are well characterized for the rel-
evant genetic markers.
The conflicting results reported for the functional con-
sequences of the rs3212227 SNP could be explained if sev-
eral polymorphisms were working together synergistically
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or antagonistically to affect IL12B mRNA and protein lev-
els or if an unidentified polymorphism at the IL12B locus
that is in LD with rs3212227 was responsible for the pso-
riasis-associated risk at this locus. Both of these explana-
tions are consistent with our observation that a second
SNP upstream of IL12B, rs6887695, independently con-
tributes to psoriasis risk and that together these two SNPs
mark a set of haplotypes with a complex hierarchy of pso-
riasis risk. To address this issue further, we are currently
conducting a detailed analysis of SNPs in high-to-mod-
erate LD with both disease-associated IL12B SNPs, to com-
plement the tag SNP and functional SNP approach de-
scribed in this article.
Both IL-12 and IL-23 have been proposed as targets for
the treatment of psoriasis. IL-12p40 antagonists have been
used for the effective treatment of a number of animal
models of inflammatory-based diseases, including a mouse
model of psoriasis,65 and monoclonal antibodies directed
against the IL-12p40 subunit are now in clinical trials for
Crohn disease, multiple sclerosis, and psoriasis.66–68 Pre-
liminary results show one of these biologics to be highly
effective for psoriasis treatment.67 However, given that
IL12B encodes the common subunit of two functionally
distinct cytokines, IL-12 and IL-23,14,54 this antibody ef-
fectively functions as a broad-spectrum immune modu-
lator, leading some to suggest that targeting only one of
these cytokine pathways may be a safer, yet equally ef-
fective, therapy.55
Biological data suggest that the IL-23 pathway may be
an important target for intervention in psoriasis. Patients
with psoriasis have significantly increased levels of IL23A
and IL12B mRNA but not IL12A mRNA in psoriatic lesions
compared with nonlesional skin, as determined by quan-
titative RT-PCR69 and confirmed by immunohistochemical
staining.70 Moreover, in a transgenic mouse model that
overexpressed IL-12p40, IL-23 but not IL-12 was observed
to be constitutively expressed by basal keratinocytes,
which are thought to play a pivotal role in psoriasis pa-
thobiology.71 The results of a recent study reporting that
intradermal administration of IL-23 but not of IL-12 in
mouse skin initiates a tumor necrosis factor–dependent
epidermal hyperplasia and psoriasform lesions supports
the notion that IL-23 dysregulation is likely to play an
important role in psoriasis pathogenesis.72
Our finding that common variants in both IL12B and
IL23R are associated with psoriasis risk provides genetic
evidence that the IL-23 pathway may be an appropriate
target for intervention in psoriasis. Given that IL23R lies
just upstream of the gene encoding the IL12-receptor–spe-
cific protein, IL12RB2, detailed fine mapping of this region
is currently under way to determine which gene or genes
directly contribute to psoriasis risk. However, review of
the CEU HapMap phase II data42 provides no evidence of
LD between rs7530511 and any IL12RB2 SNPs and evi-
dence of only modest LD between rs1120926 and a single
IL12RB2 intronic SNP, rs2001257 ( ).2r p 0.253
Duerr and colleagues73 recently reported strong associ-
ation between one of the psoriasis-associated IL23R SNPs
(rs11209026, Q381R) described here and risk of inflam-
matory bowel disease. No association was observed with
the other IL23R SNP described here (rs7530511, L310P),
and haplotypes were not evaluated. Together, these data
are intriguing and add further support to the hypothesis
that there are common genetic variants that contribute
to general immune dysregulation and susceptibility to
autoimmunity.74,75 Given the role of IL-23 and IL-12 in
murine experimental autoimmune encephalomyelitis,76,77
these IL12B and IL23R variants merit evaluation in studies
of multiple sclerosis as well as other autoimmune diseases.
In conclusion, we provide convincing statistical support
for two psoriasis-susceptibility loci—one in 5q31.1-q33.1
(IL12B region) and the other in 1p31.3 (IL23R region)—
and preliminary analyses suggest that the combination of
risk and protective haplotypes at both loci can lead to a
more-than-threefold differential risk for disease. These
data provide additional justification for targeting both the
IL-12 and IL-23 pathways with new psoriasis therapeutics
and suggest that targeting IL-23 or downstream effector
cytokines may directly target the disease pathway and
prove efficacious for the treatment of psoriasis. Finally, it
will be important to determine whether any of the iden-
tified IL12B and IL23R psoriasis-associated alleles are also
associated with response to anti–IL-12p40 therapy and/or
the most effective dosage of this antibody.
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Accession numbers and URLs for data presented herein are as
follows:
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/ (for SNPs rs10035989,
rs1109918, rs11171806, rs11209026, rs11575926, rs11744690,
rs1368437, rs1422668, rs1422878, rs1433048, rs17860508,
rs1833754, rs1884444, rs1897565, rs2043270, rs2161357,
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Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
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terial disease)
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SNPAnalyzer, http://snp.istech.info/
References
1. Lebwohl M (2003) Psoriasis. Lancet 361:1197–1204
2. Bowcock AM (2005) The genetics of psoriasis and autoim-
munity. Annu Rev Genomics Hum Genet 6:93–122
3. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005)
Psoriasis arthritis: epidemiology, clinical features, course, and
outcome. Ann Rheum Dis 64:ii14–ii17
4. Bhalerao J, Bowcock AM (1998) The genetics of psoriasis: a
complex disorder of the skin and immune system. Hum Mol
Genet 7:1537–1545
5. Bowcock AM, Krueger JG (2005) Getting under the skin: the
immunogenetics of psoriasis. Nat Rev Immunol 5:699–711
6. Helms C, Saccone NL, Cao L, Daw JA, Cao K, Hsu TM, Taillon-
Miller P, Duan S, Gordon D, Pierce B, et al (2005) Localization
of PSORS1 to a haplotype block harboring HLA-C and distinct
from corneodesmosin and HCR. Hum Genet 118:466–476
7. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch
S, Weichenthal M, Abecasis GR, Lim HW, Christophers E, et
al (2006) Sequence and haplotype analysis supports HLA-C
as the psoriasis susceptibility 1 gene. Am J Hum Genet 78:
827–851
8. Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gor-
don D, Heffernan M, Daw JA, Robarge J, Ott J, et al (2003) A
putative RUNX1 binding site variant between SLC9A3R1 and
NAT9 is associated with susceptibility to psoriasis. Nat Genet
35:349–356
9. Hewett D, Samuelsson L, Polding J, Enlund F, Smart D, Can-
tone K, See CG, Chadha S, Inerot A, Enerback C, et al (2002)
Identification of a psoriasis susceptibility candidate gene by
linkage disequilibrium mapping with a localized single nu-
cleotide polymorphism map. Genomics 79:305–314
10. Hirschhorn JN, Daly MJ (2005) Genome-wide association
studies for common diseases and complex traits. Nat Rev Ge-
net 6:95–108
11. Long AD, Langley CH (1999) The power of association studies
to detect the contribution of candidate genetic loci to vari-
ation in complex traits. Genome Res 9:720–731
12. Risch N, Merikangas K (1996) The future of genetic studies
of complex human diseases. Science 273:1516–1517
13. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H,
Asano N, Kishimoto M, Tanida Y, Kakinuma T, et al (2002)
Interleukin-12 p40 gene (IL12B) 3′-untranslated region poly-
morphism is associated with susceptibility to atopic derma-
titis and psoriasis vulgaris. J Dermatol Sci 30:161–166
14. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B,
Vega F, Yu N, Wang J, Singh K, et al (2000) Novel p19 protein
engages IL12p40 to form a cytokine, IL-23, with biological
activities similar as well as distinct from IL-12. Immunity 13:
715–725
15. Germer S, Holland MJ, Higuchi R (2000) High-throughput
SNP allele-frequency determination in pooled DNA samples
by kinetic PCR. Genome Res 10:258–266
16. Shiffman D, Ellis SG, Rowland CM, Malloy MJ, Luke MM,
Iakoubova OA, Pullinger CR, Cassano J, Aouizerat BE, Fen-
wick RG, et al (2005) Identification of four gene variants as-
sociated with myocardial infarction. Am J Hum Genet 77:
596–605
17. Bustamante CD, Fledel-Alon A, Williamson S, Nielsen R, Hu-
bisz MT, Glanowski S, Tanenbaum DM, White TJ, Sninsky JJ,
Hernandez RD, et al (2005) Natural selection on protein-cod-
ing genes in the human genome. Nature 437:1153–1157
18. Li Y, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C,
Schrodi S, Leong D, Lau K, Cantanese J, et al (2004) Associ-
ation of ABCA1 with late-onset Alzheimer’s disease is not
observed in a case-control study. Neurosci Lett 366:268–271
19. Carlton VEH, Hu X, Chokkalingam AP, Schrodi SJ, Brandon
R, Alexander HC, Chang M, Catanese JJ, Leong DU, Ardlie
KG, et al (2005) PTPN22 genetic variation: evidence for mul-
tiple variants associated with rheumatoid arthritis. Am J Hum
Genet 77:567–581
20. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general
users and for biologist programmers. In: Krawetz S, Misener
S (eds) Bioinformatics methods and protocols: methods in
molecular biology. Humana Press, Totowa, NJ, pp 365–386
21. Hu X, Schrodi SJ, Ross DA, Cargill, M (2004) Selecting tagging
SNPs for association studies using power calculations from
genotype data. Hum Hered 57:156–170
22. Abecasis GR, Cookson WO (2000) GOLD—graphical over-
view of linkage disequilibrium. Bioinformatics 16:182–183
23. Yoo J, Seo B, Kim Y (2005) SNPAnalyzer: a web-based inte-
grated workbench for single-nucleotide polymorphism anal-
ysis. Nucleic Acids Res 33:W483–W488
24. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA
(2002) Score tests for association between traits and haplo-
types when linkage phase is ambiguous. Am J Hum Genet
70:425–434
25. Fisher RA (1954) Statistical methods for research workers,
12th ed. Oliver and Boyd, Edinburgh
26. Sokal RR, Rohlf FJ (1995) Biometry, 3rd ed. W. H. Freeman
and Company, New York
27. Weir BS (1996) Genetic data analysis II. Sinauer, Sunderland,
MA
28. Nielsen DM, Ehm MG, Zaykin DV, Weir BS (2004) Effect of
two- and three-locus linkage disequilibrium on the power to
detect marker/phenotype associations. Genetics 168:1029–
1040
29. Breslow NE, Day NE (1980) Statistical methods in cancer re-
search. Vol I. The analysis of case-control studies. Interna-
tional Agency for Research on Cancer, Lyon
www.ajhg.org The American Journal of Human Genetics Volume 80 February 2007 289
30. Walter SD (1975) The distribution of Levin’s measure of at-
tributable risk. Biometrika 62:371–374
31. Schlesselman JJ (1982) Case-control studies: design, conduct,
analysis. Oxford University Press, New York
32. Schrodi SJ (2005) A probabilistic approach to large-scale as-
sociation scans: a semi-Bayesian method to detect disease-
predisposing alleles. Stat Appl Genet Mol Biol 4:Article31
33. Efron B, Tibshirani R, Storey JD, Tusher V (2001) Empirical
Bayes analysis of a microarray experiment. J Am Stat Assoc
96:1151–1160
34. Devlin B, Roeder K (1999) Genomic control for association
studies. Biometrics 55:997–1004
35. Thomson G, Robinson WP, Kuhner MK, Joe S, MacDonald
MJ, Gottschall JL, Barbosa J, Rich SS, Bertrams J, Baur MP, et
al (1988) Genetic heterogeneity, modes of inheritance, and
risk estimates for a joint study of Caucasians with insulin-
dependent diabetes mellitus. Am J Hum Genet 43:799–816
36. Valdes AM, Thomson G (1997) Detecting disease-predispos-
ing variants: the haplotype method. Am J Hum Genet 60:
703–716
37. Jeffreys H (1935) Some tests of significance, treated by the
theory of probability. Proc Camb Philol Soc 31:203–222
38. Kass R, Raftery A (1995) Bayes factors and model uncertainty.
J Am Stat Assoc 90:773–795
39. Ahmad T, Neville M, Marshall SE, Armuzzi A, Mulcahy-Hawes
K, Crawshaw J, Sato H, Ling KL, Barnardo M, Goldthorpe S,
et al (2003) Haplotype-specific linkage disequilibrium pat-
terns define the genetic topography of the human MHC.
Hum Mol Genet 12:647–656
40. Altare F, Lammas D, Revy P, Jouanguy E, Doffinger R, Lam-
hamedi S, Drysdale P, Scheel-Toellner D, Girdlestone J, Dar-
byshire P, et al (1998) Inherited interleukin 12 deficiency in
a child with bacille Calmette-Guerin and Salmonella enteritidis
disseminated infection. J Clin Invest 102:2035–2040
41. Picard C, Fieschi C, Altare F, Al-Jumaah S, Al-Hajjar S, Feinberg
J, Dupuis S, Soudais C, Al-Mohsen IZ, Genin E, et al (2002)
Inherited interleukin-12 deficiency: IL12B genotype and clin-
ical phenotype of 13 patients from six kindreds. Am J Hum
Genet 70:336–348
42. The International HapMap Consortium (2005) A haplotype
map of the human genome. Nature 437:1299–1320
43. Huang D, Cancilla MR, Morahan G (2000) Complete primary
structure, chromosomal localisation, and definition of poly-
morphisms of the gene encoding the human interleukin-12
p40 subunit. Genes Immun 1:515–520
44. Morahan G, Huang D, Wu M, Holt BJ, White GP, Kendall GE,
Sly PD, Holt PG (2002) Association of IL12B promoter poly-
morphism with severity of atopic and non-atopic asthma in
children. Lancet 360:455–459
45. Litjens NH, van der Plas MJ, Ravensbergen B, Numan-Ruberg
SC, van Assen Y, Thio HB, van Dissel JT, van de Voss E, Nib-
bering PH (2004) Psoriasis is not associated with IL-12p70/
IL-12p40 production and IL12B promoter polymorphism. J
Invest Dermatol 122:923–926
46. Muller-Berghaus J, Kern K, Paschen A, Nguyen XD, Kluter H,
Morahan G, Schadendorf D (2004) Deficient IL-12p70 secre-
tion by dendritic cells based on IL12B promoter genotype.
Genes Immun 5:431–434
47. Yilmaz V, Yentur SP, Saruhan-Direskeneli G (2005) IL-12 and
IL-10 polymorphisms and their effects on cytokine produc-
tion. Cytokine 30:188–194
48. Begovich AB, Carlton VEH, Honigberg LA, Schrodi SJ, Chok-
kalingam AP, Alexander HC, Ardlie KG, Qiqing H, Smith AM,
Spoerke JM, et al (2004) A missense single-nucleotide poly-
morphism in a gene encoding a protein tyrosine phosphatase
(PTPN22) is associated with rheumatoid arthritis. Am J Hum
Genet 75:330–337
49. Shiffman D, Rowland CM, Louie JZ, Luke MM, Bare LA, Bo-
lonick JI, Young BA, Catanese JJ, Stiggins CF, Pullinger CR, et
al (2006) Gene variants of VAMP8 and HNRPUL1 are associ-
ated with early-onset myocardial infarction. Arterioscler
Thromb Vasc Biol 26:1613–1618
50. Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S,
Abar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, et al
(2006) Identification of two gene variants associated with risk
of advanced fibrosis in patients with chronic hepatitis C. Gas-
troenterology 130:1679–1687
51. Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JS, Smemo S,
Hinrichs A, Tacey K, Toombs TA, Kwok S, et al (2006) DAPK1
variants are associated with Alzheimer’s disease and allele-
specific expression. Hum Mol Genet 15:2560–2568
52. Veal CD, Clough RL, Barber RC, Mason S, Tillman D, Ferry
B, Jones AB, Ameen M, Balendran N, Powis SH, et al (2001)
Identification of a novel psoriasis susceptibility locus at 1p
and evidence of epistasis between PSORS1 and candidate loci.
J Med Genet 38:7–13
53. Yip SY (1984) The prevalence of psoriasis in the Mongoloid
race. J Am Acad Dermatol 10:965–968
54. Hunter CA (2005) New IL-12-family members: IL-23 and IL-
27, cytokines with divergent functions. Nat Rev Immunol 5:
521–531
55. Bowman EP, Chackerian AA, Cua DJ (2006) Rationale and
safety of anti-interleukin-23 and anti-interleukin-17A ther-
apy. Curr Opin Infect Dis 19:245–252
56. Morahan G, Huang D, Ymer SI, Cancilla MR, Stephen K, Da-
badghao P, Werther G, Tait BD, Harrison LC, Colman PG
(2001) Linkage disequilibrium of a type 1 diabetes suscepti-
bility locus with a regulatory IL12B allele. Nat Genet 27:218–
221
57. Randolph AG, Lange C, Silverman EK, Lazarus R, Silverman
ES, Raby B, Brown A, Ozonoff A, Richter B, Weiss ST (2004)
The IL12B gene is associated with asthma. Am J Hum Genet
75:709–715
58. Mueller T, Mas-Marques A, Sarrazin C, Wiese M, Halangk J,
Witt H, Ahlenstiel G, Spengler U, Goebel U, Wiedenmann B,
et al (2004) Influence of interleukin 12B (IL12B) polymor-
phisms on spontaneous and treatment-induced recovery
from hepatitis C virus infection. J Hepatol 41:652–658
59. Hall MA, McGlinn E, Coakley G, Fisher SA, Boki K, Middleton
D, Kaklamani E, Moutsopoulos H, Loughran TP Jr, Ollier WE,
et al (2000) Genetic polymorphism of IL-12 p40 gene in im-
mune-mediated disease. Genes Immun 1:219–224
60. Orozco G, Gonzalez-Gay MA, Paco L, Lopez-Nevot MA, Guz-
man M, Pascual-Salcedo D, Balsa A, Martin J (2005) Interleu-
kin 12 (IL12B) and interleukin 12 receptor (IL12RB1) gene
polymorphisms in rheumatoid arthritis. Hum Immunol 66:
710–715
61. Seegers D, Zwiers A, Strober W, Pena AS, Bouma G (2002) A
TaqI polymorphism in the 3′UTR of the IL-12 p40 gene cor-
relates with increased IL-12 secretion. Genes Immun 3:419–
423
62. Zwiers A, Seegers D, Heijmans R, Koch A, Hampe J, Nikolaus
S, Pena AS, Schreiber S, Bouma G (2004) Definition of poly-
morphisms and haplotypes in the interleukin-12B gene: as-
290 The American Journal of Human Genetics Volume 80 February 2007 www.ajhg.org
sociation with IL-12 production but not with Crohn’s disease.
Genes Immun 5:675–677
63. Sanchez E, Morales S, Paco L, Lopez-Nevot MA, Hidalgo C,
Jimenez-Alonso J, Torres B, Gonzalez-Gay MA, Callejas JL,
Ortego-Centeno N, et al (2005) Interleukin 12 (IL12B), in-
terleukin 12 receptor (IL12RB1) and interleukin 23 (IL23A)
gene polymorphism in systemic lupus erythematosus. Rheu-
matology 44:1136–1139
64. Stanilova S, Miteva L (2005) Taq-I polymorphism in 3′UTR
of the IL-12B and association with IL-12p40 production from
human PBMC. Genes Immun 6:364–366
65. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO (1999)
IL-12, independently of IFN-g, plays a crucial role in the path-
ogenesis of a murine psoriasis-like skin disorder. J Immunol
162:7480–7491
66. Winterfield LS, Menter A, Gordon K, Gottlieb A (2005) Pso-
riasis treatment: current and emerging directed therapies.
Ann Rheum Dis 64:ii87–ii90
67. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD,
Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, et
al (2004) A phase I study evaluating the safety, pharmaco-
kinetics, and clinical response of a human IL-12 p40 antibody
in subjects with plaque psoriasis. J Invest Dermatol 123:1037–
1044
68. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present
D, Dolin B, Goodman N, Groden C, Hornung RL, et al (2004)
Anti-interleukin-12 antibody for active Crohn’s disease. N
Engl J Med 351:2069–2079
69. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F,
Chamian F, Dhodapkar M, Krueger JG (2004) Increased ex-
pression of interleukin 23 p19 and p40 in lesional skin of
patients with psoriasis vulgaris. J Exp Med 199:125–130
70. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB (2006)
In vitro and in situ expression of IL-23 by keratinocytes in
healthy skin and psoriasis lesions: enhanced expression in
psoriatic skin. J Immunol 176:1908–1915
71. Kopp T, Lenz P, Bello-Fernandez C, Kastelein RA, Kupper TS,
Stingl G (2003) IL-23 production by cosecretion of endoge-
nous p19 and transgenic p40 in keratin 14/p40 transgenic
mice: evidence for enhanced cutaneous immunity. J Immu-
nol 170:5438–5444
72. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski
M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB,
et al (2006) IL-23 stimulates epidermal hyperplasia via TNF
and IL-20R2-dependent mechanisms with implications for
psoriasis pathogenesis. J Exp Med 203:2577–2587
73. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly
MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, et al
(2006) A genome-wide association study identifies IL23R as
an inflammatory bowel disease gene. Science 314:1461–1463
74. Marrack P, Kappler J, Kotzin BL (2001) Autoimmune disease:
why and where it occurs. Nat Med 7:899–905
75. Wandstrat A, Wakeland E (2001) The genetics of complex
autoimmune disease: non-MHC susceptibility genes. Nat Im-
munol 2:802–809
76. Becher B, Durell BG, Noelle RJ (2002) Experimental auto-
immune encephalitis and inflammation in the absence of
interleukin-12. J Clin Invest 110:493–498
77. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour
B, Lucian L, To W, Kwan S, Churakova T, et al (2003) Inter-
leukin-23 rather than interleukin-12 is the critical cytokine
for autoimmune inflammation of the brain. Nature 421:744–
748
